In A Nutshell Men have double the odds of presenting with stage III multiple myeloma compared to women, even after accounting ...

At age 89, Cal Crow plays water volleyball three days a week, then chases that with a 1,000-foot swim; on his off days, he logs at least a mile around his neighborhood — and that’s with a cancer ...

Despite significant improvement in the outcomes of patients with newly diagnosed multiple myeloma (NDMM) with novel therapies, there is still an underserved high-risk (HR) population that experiences ...

Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)–directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory multiple myeloma. We ...

Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and ...